Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 67% of modeled bridge. Strengths: Occupancy Rate, Bed Count. Risks: Revenue per Bed, Net-to-Gross Ratio. Risk-adjusted uplift: $0.8M (vs $1.1M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $435K | $435K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $418K | $12K | $430K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $67K | $198K | $264K | $834K | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $14K | $14K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 45.1% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $109K | $217K | $326K | $435K | $435K | $435K | $435K |
| Denial Rate Reduction | $0 | $108K | $215K | $323K | $430K | $430K | $430K | $430K |
| A/R Days Reduction | $0 | $88K | $176K | $264K | $264K | $264K | $264K | $264K |
| Clean Claim Rate | $0 | $7K | $14K | $14K | $14K | $14K | $14K | $14K |
| Cumulative | $0 | $311K | $623K | $927K | $1.1M | $1.1M | $1.1M | $1.1M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $1.1M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 46% / 6.6x | 51% / 7.7x | 55% / 8.8x | 56% / 9.4x | 58% / 9.9x |
| 9.0x | 41% / 5.5x | 45% / 6.5x | 50% / 7.5x | 51% / 8.0x | 53% / 8.5x |
| 10.0x | 36% / 4.7x | 41% / 5.5x | 45% / 6.4x | 47% / 6.8x | 49% / 7.3x |
| 11.0x | 32% / 3.9x | 36% / 4.7x | 41% / 5.5x | 43% / 5.9x | 45% / 6.3x |
| 12.0x | 27% / 3.3x | 32% / 4.1x | 37% / 4.8x | 39% / 5.2x | 41% / 5.5x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline -9% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 7.1x, adding 1.4 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $6.0M | — | $6.0M | 27.5% |
| Year 1 | $6.2M | +$762K | $6.9M | 31.9% |
| Year 2 | $6.3M | +$1.1M | $7.5M | 34.5% |
| Year 3 | $6.5M | +$1.1M | $7.7M | 35.4% |
| Year 4 | $6.7M | +$1.1M | $7.9M | 36.3% |
| Year 5 | $6.9M | +$1.1M | $8.1M | 37.2% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $217K | $326K | $435K | $522K |
| Denial Rate Reductio | $215K | $323K | $430K | $516K |
| A/R Days Reduction | $132K | $198K | $264K | $317K |
| Clean Claim Rate | $7K | $10K | $14K | $17K |
| Total | $572K | $857K | $1.1M | $1.4M |
Peer Context — Where This Hospital Sits
Key metrics vs 110 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 27.5% | -13.6% | -1.4% | 10.1% | P95 |
| Net-to-Gross | 64.7% | 26.1% | 35.9% | 45.1% | P98 |
| Occupancy | 57.4% | 27.4% | 44.9% | 65.4% | P66 |
| Rev/Bed | $435K | $386K | $950K | $1.6M | P29 |
| Exp/Bed | $315K | $368K | $928K | $1.8M | P19 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.